Description
Ranolazine exhibits anti-anginal, anti-arrhythmic, and cardioprotective activities; it is clinically used to treat angina pectoris. Ranolazine inhibits the late Na+ current (Nav1.7 and Nav1.7 channels) and subsequent intracellular Ca2+ accumulation. In hypertensive rats, ranolazine decreases end diastolic pressure, improving diastolic function and decreasing free Ca2+ levels. In other animal models, ranolazine inhibits induction of atrial flutter and atrial fibrillation.